Kathleen Laporte net worth and biography

Kathleen Laporte Biography and Net Worth

Director of 89bio

Kathy LaPorte brings over 30 years of experience in executive leadership and venture investing within the biotech industry. Ms. LaPorte previously served as Chief Executive Officer and Board Member of Nodality Inc. Ms. LaPorte was a Founding Partner of New Leaf Venture Partners, which was a spin-out from the Sprout Group, where she served as a General Partner. She has extensive Board experience and currently serves on the Boards of Bolt Biotherapeutics (NASDAQ: BOLT), Precipio Inc., (NASDAQ: PRPO), and Phoenix Biotech Acquisition Corporation (NASDAQ: PBAXU). Additionally, Ms. LaPorte has served on multiple public boards including Onyx Pharmaceuticals (NASDAQ: ONXX), Affymax (NASDAQ: AFFY), and ISTA Pharmaceuticals (NASDAQ: ISTA). Ms. LaPorte received her MBA from the Stanford University Graduate School of Business and her B.S. in Biology from Yale University.

How do I contact Kathleen Laporte?: The corporate mailing address for Laporte and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at investors@89bio.com. Learn More on Kathleen Laporte's contact information.
Has Kathleen Laporte been buying or selling shares of 89bio?: Kathleen Laporte has not been actively trading shares of 89bio during the last ninety days. Most recently, Kathleen Laporte sold 12,500 shares of the business's stock in a transaction on Monday, July 17th. The shares were sold at an average price of $18.80, for a transaction totalling $235,000.00. Learn More on Kathleen Laporte's trading history.
Who are 89bio's active insiders?: 89bio's insider roster includes Gregory Grunberg (Director), Michael Hayden (Director), Morrow III (Director), Kathleen Laporte (Director), Ryan Martins (CFO), Charles Mcwherter (Director), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.
Are insiders buying or selling shares of 89bio?: In the last twelve months, 89bio insiders bought shares 5 times. They purchased a total of 5,744,285 shares worth more than $50,235,693.75. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 10,963 shares worth more than $71,149.87. The most recent insider tranaction occured on January, 30th when Director Ra Capital Management, L.P. bought 5,714,285 shares worth more than $49,999,993.75. Insiders at 89bio own 2.8% of the company. Learn More about insider trades at 89bio.
Information on this page was last updated on 1/30/2025.

Kathleen Laporte Insider Trading History at 89bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/17/2023	Sell	12,500	$18.80	$235,000.00

Kathleen Laporte Buying and Selling Activity at 89bio

89bio Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Today's Range

Now: $8.01

$7.87

$9.21

50 Day Range

MA: $9.03

$6.09

$11.66

2 Week Range

Now: $8.01

$5.99

$11.84

Volume

2,294,476 shs

Average Volume

1,185,739 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield